Journal Article

Isoniazid Hepatotoxicity among Drug Users: The Role of Hepatitis C

Alberto Fernández-Villar, Bernardo Sopeña, Rafael Vázquez, Fernando Ulloa, Enrique Fluiters, Mar Mosteiro, Martínez-Vázquez César and Luis Piñeiro

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 36, issue 3, pages 293-298
Published in print February 2003 | ISSN: 1058-4838
Published online February 2003 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/345906
Isoniazid Hepatotoxicity among Drug Users: The Role of Hepatitis C

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

The incidence of and risk factors associated with hepatotoxicity in patients with chronic hepatitis have not been systematically studied. Therefore, we conducted a prospective study that included former drug users who were treated with isoniazid for latent tuberculosis infection. Of 415 patients, 20 (4.8%; 95% confidence interval [CI], 3–7.4) had hepatotoxicity diagnosed, and 6 (1.4%; 95% CI, 0.5–3.2) developed clinical hepatitis, none of whom had serious symptoms. The only 2 factors independently associated with isoniazid hepatotoxicity were excessive alcohol consumption (odds ratio [OR]; 4.2, 95% CI, 1.6–10.8; P = .002) and a high baseline alanine transaminase level (OR, 4.3; 95% CI, 1.6–11.4; P = .002). The presence of hepatitis C virus antibodies was associated with hepatotoxicity only on univariate analysis. Treatment with isoniazid in drug users appears to be safe and well tolerated, although frequent asymptomatic elevations in transaminase levels were observed.

Journal Article.  3831 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.